Heart failure patients need new treatments, and research has shown that cardiac gene therapy is a promising way to improve the contractility of patients’ heart muscles by targeting in regulation of sarcoendoplasmic reticulum ATPase (Zsebo et al., 2014) and phospholamban (Tsuji et al., 2009; Kairouz et al., 2012), protein phosphatase inhibitor1 correlating with beta-adrenergic system (Ishikawa et al., 2014; Watanabe et al., 2017). Here, PLN is linked to heart failure.